Genetic Factors and HIV-1 Treatment Success in TB/HIV Patients
Author Information
Author(s): Ridolfi Felipe, Amorim Gustavo, Haas David W., Arriaga Maria, Staats Cody, Cordeiro-Santos Marcelo, Kritski Afrânio L., Figueiredo Marina C., Andrade Bruno B., Sterling Timothy R., Rolla Valeria C.
Primary Institution: RePORT-Brazil
Hypothesis
Can genetic variants of antiretroviral therapy (ART) affect HIV-1 outcomes among TB/HIV patients?
Conclusion
The study found that the proportion of participants achieving virologic suppression was low, and genetic variants affecting ART metabolism were not significantly associated with treatment success.
Supporting Evidence
- Among 194 TB/HIV participants, 32% did not achieve HIV-1 virologic suppression.
- Efavirenz was the most frequently used NNRTI, while raltegravir was the most common INSTI.
- The median time to virologic suppression was 184 days for efavirenz and 188 days for INSTI.
Takeaway
This study looked at how people's genes might affect their HIV treatment when they also have tuberculosis, and it found that many didn't get better.
Methodology
Participants were genotyped for specific genetic variants and their virologic suppression was measured after starting ART.
Limitations
The overall virologic suppression was suboptimal, and the study did not find significant associations between genetic variants and treatment outcomes.
Participant Demographics
Participants were TB/HIV patients receiving standard TB treatment and ART.
Statistical Information
P-Value
0.84
Confidence Interval
95% CI 160-207 for efavirenz, 95% CI 144-231 for INSTI
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website